Heidelberg Pharma AG: Heidelberg Pharma AG (WL6, Frankfurt Stock Exchange), based in Ladenburg, Germany, is a leading biotech company pioneering the use of its ATAC (Antibody Targeted Amanitin Conjugate) platform to develop novel cancer treatments with a unique mode of action effective at specifically killing both inactive and dividing cancers cells and overcoming tumour resistance mechanisms. The platform can be applicable across many cancer types and has a specific genetic biomarker that confers high tumour cell susceptibility to the therapy in many cancer types. Heidelberg Pharma is accelerating development of an internal pipeline of ATACs. Lead product HDP-101, for blood cancer, is expected to enter phase I studies by end 2020. It also has several out-licensed programs using ATAC and antibody drug conjugate technology expected to generate long term income streams and early technology validation